BRCA1-IRIS overexpression promotes formation of aggressive breast cancers.
INTRODUCTION: Women with HER2(+) or triple negative/basal-like (TN/BL) breast cancers succumb to their cancer rapidly due, in part to acquired Herceptin resistance and lack of TN/BL-targeted therapies. BRCA1-IRIS is a recently discovered, 1399 residue, BRCA1 locus alternative product, which while sh...
Main Authors: | Yoshiko Shimizu, Hugh Luk, David Horio, Penelope Miron, Michael Griswold, Dirk Iglehart, Brenda Hernandez, Jeffrey Killeen, Wael M ElShamy |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3325250?pdf=render |
Similar Items
-
The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells
by: Daniel Ryan, et al.
Published: (2019-04-01) -
The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion
by: Danielle Bogan, et al.
Published: (2017-05-01) -
Aggressiveness Niche: Can It Be the Foster Ground for Cancer Metastasis Precursors?
by: Wael M. ElShamy, et al.
Published: (2016-01-01) -
Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative.
by: Zannel Blanchard, et al.
Published: (2014-01-01) -
HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.
by: Petra van der Groep, et al.
Published: (2013-01-01)